Semaglutide is a long-acting GLP-1 receptor agonist whose mechanistic interpretation can be positioned within the broader biology of incretin signaling. A comparison with incretin-based agents requires distinction between GLP-1 receptor activity, GIP receptor activity, and combined receptor engagement. The relevant framework includes GLP-1 biology, receptor signaling, mechanism, pharmacodynamics, endocrine physiology, and gastrointestinal signaling.
Semaglutide-versus-incretin interpretation also involves how receptor engagement intersects with insulin secretion, glucagon regulation, gastric motor function, and central appetite circuitry. These domains can be considered alongside pharmacokinetics, clinical pharmacology, glycemic control, and appetite regulation. The comparison is mechanistic rather than outcome-oriented, emphasizing pathway architecture and exposure-response relationships rather than therapeutic ranking.
At the systems level, incretin comparisons connect receptor pharmacology with glucose homeostasis, gastrointestinal physiology, energy-intake signaling, and metabolic regulation. Interpretation can therefore incorporate glycemic variability, insulin resistance, metabolic outcomes, and relevant clinical trials as evidence contexts. The central distinction is whether observed physiology is attributable to GLP-1 signaling, GIP signaling, dual receptor engagement, exposure characteristics, or interacting downstream pathways.
Semaglutide-versus-incretin interpretation begins by defining incretin biology as a family of nutrient-responsive endocrine signaling processes rather than a single pharmacologic mechanism. Semaglutide primarily engages the GLP-1 receptor, while other incretin-based agents may engage GLP-1 receptors, GIP receptors, or both. This distinction can be framed through GLP-1 biology, mechanism, clinical pharmacology, pharmacodynamics, and receptor-level signal transduction.
A mechanistic comparison separates receptor identity from downstream physiology. GLP-1 receptor and GIP receptor signaling both involve class B G protein-coupled receptor biology, but receptor distribution, intracellular coupling, tissue context, and physiological roles differ. Dual agonism introduces simultaneous receptor engagement and potential pathway interaction. These distinctions intersect with endocrine pathways only when such a page is available, so the present framework instead emphasizes glycemic control, appetite regulation, metabolic outcomes, and mechanism.
The comparison is also shaped by exposure characteristics. A ligand can produce different temporal patterns of receptor stimulation depending on absorption, distribution, metabolism, elimination, molecular stability, and receptor pharmacology. Accordingly, pharmacokinetics and pharmacodynamics provide complementary perspectives. Interpretation may additionally consider glycemic variability, insulin resistance, weight management, and clinical trials without converting mechanistic evidence into treatment conclusions.
| Mechanistic dimension | Primary comparison | Interpretive focus |
|---|---|---|
| Receptor pharmacology | GLP-1 receptor, GIP receptor, or both | Ligand-receptor engagement and signaling |
| Physiological signaling | Endocrine, gastrointestinal, appetite, metabolic | Tissue-specific pathway integration |
| Exposure-response | PK linked to PD | Temporal receptor stimulation and response relationships |
GLP-1 and GIP are endogenous incretin hormones with overlapping but nonidentical receptor biology. Semaglutide is designed around sustained GLP-1 receptor activation, making receptor selectivity central to its mechanistic profile. GIP receptor biology represents a complementary incretin pathway with distinct tissue expression and signaling context. Relevant interpretive domains include GLP-1 biology, mechanism, clinical pharmacology, pharmacodynamics, and appetite regulation.
At the cellular level, both GLP-1 and GIP receptors belong to the class B1 family of GPCRs and can stimulate adenylyl cyclase through Gs-associated signaling, increasing intracellular cyclic AMP. Downstream protein kinase A and exchange protein directly activated by cAMP pathways can modulate secretory machinery and cellular responses. The physiological consequences depend on cell type and context, connecting receptor pharmacology with glycemic control, insulin resistance, metabolic outcomes, and mechanism.
Comparative interpretation should avoid treating GLP-1 and GIP signaling as interchangeable. Receptor distribution, ligand exposure, receptor trafficking, signal duration, endogenous hormone physiology, and tissue-specific coupling can alter the functional meaning of receptor activation. These variables can be examined through pharmacokinetics, pharmacodynamics, clinical trials, glycemic variability, and appetite regulation, while maintaining a distinction between mechanistic observations and clinical endpoints.
| Feature | GLP-1 receptor | GIP receptor |
|---|---|---|
| Receptor family | Class B1 GPCR | Class B1 GPCR |
| Major intracellular pathway | cAMP-linked signaling | cAMP-linked signaling |
| Interpretive context | Endocrine, gastrointestinal, appetite and metabolic signaling | Endocrine and metabolic signaling with distinct tissue context |
Dual-agonist biology differs from selective GLP-1 receptor agonism because two incretin receptors are pharmacologically engaged. Semaglutide provides a useful reference point for isolating GLP-1 receptor-mediated mechanisms, whereas dual agonists introduce concurrent GLP-1 and GIP receptor activation. Interpretation therefore depends on GLP-1 biology, receptor pharmacology, mechanism, pharmacodynamics, and clinical pharmacology.
Dual receptor activation does not simply represent an arithmetic addition of two isolated pathways. Receptor abundance, cellular co-expression, ligand concentration, receptor occupancy, intracellular signal amplification, desensitization, and tissue-specific physiology can influence pathway interaction. Endocrine signaling may therefore involve coordinated effects on pancreatic islet cells and other target tissues. These mechanisms can be related to glycemic control, insulin resistance, metabolic outcomes, and appetite regulation.
PK/PD interpretation is particularly important when comparing selective and dual incretin pharmacology. Molecular structure can affect circulating exposure, receptor residence, proteolytic stability, distribution, and elimination, while pharmacodynamics reflects the integrated biological response. Comparative evidence may therefore be interpreted alongside pharmacokinetics, pharmacodynamics, glycemic variability, clinical trials, and effectiveness overview without treating those evidence domains as mechanistic equivalence.
| Architecture | Selective GLP-1 agonism | Dual incretin agonism |
|---|---|---|
| Primary receptor engagement | GLP-1 receptor | GLP-1 and GIP receptors |
| Signaling context | Predominantly GLP-1-mediated | Integrated dual-receptor signaling |
| Interpretive variable | GLP-1 receptor exposure-response | Relative receptor engagement and pathway interaction |
Endocrine comparison centers on how incretin receptor activation modifies pancreatic islet signaling and glucose-dependent hormone secretion. GLP-1 receptor activation can enhance glucose-dependent insulin secretion and influence glucagon physiology, while GIP receptor activation engages related but distinct endocrine mechanisms. Semaglutide interpretation therefore intersects with GLP-1 biology, mechanism, glycemic control, insulin resistance, and clinical pharmacology.
The glucose dependence of incretin-mediated insulin secretion is a key mechanistic distinction from pathways that directly stimulate insulin secretion independently of ambient glucose. At the beta cell, receptor activation can increase cyclic AMP and amplify glucose-triggered secretory processes. Alpha-cell signaling and glucagon regulation add another layer of complexity. These relationships can be studied using pharmacodynamics, glycemic variability, type 2 diabetes, and prediabetes as physiological contexts.
Endocrine interpretation also requires separation of direct receptor effects from secondary consequences of altered nutrient flux, gastric emptying, appetite signaling, and insulin sensitivity. A change in circulating glucose or insulin can therefore represent an integrated systems response rather than a single receptor event. Mechanistic analysis can incorporate metabolic outcomes, pharmacokinetics, pharmacodynamics, clinical trials, and glycemic control while maintaining pathway-level neutrality.
| Endocrine component | Mechanistic relationship | Comparison variable |
|---|---|---|
| Beta cell | cAMP-amplified glucose-dependent insulin secretion | Receptor-specific signaling |
| Alpha cell | Incretin-linked modulation of glucagon physiology | Ligand and glucose context |
| Whole-body glucose regulation | Integrated insulin, glucagon, nutrient and hepatic pathways | PK/PD and physiological state |
Gastrointestinal interpretation is an important component of incretin pharmacology because GLP-1 signaling participates in regulation of gastric motor activity, gastric emptying, intestinal signaling, and gut-brain communication. Semaglutide-associated GLP-1 receptor activation can therefore be interpreted through GLP-1 biology, mechanism, pharmacodynamics, clinical pharmacology, and appetite regulation.
GIP receptor biology overlaps with endocrine incretin signaling but has a different physiological distribution and gastrointestinal relationship. Comparative interpretation should distinguish direct gastrointestinal receptor activity from indirect changes caused by altered nutrient delivery, gastric distension, vagal signaling, and postprandial endocrine feedback. These mechanisms connect with pharmacokinetics, glycemic control, glycemic variability, mechanism, and metabolic outcomes.
The temporal relationship between drug exposure and gastrointestinal signaling is also relevant. Receptor stimulation can vary according to circulating concentration, tissue exposure, receptor sensitivity, neural integration, and adaptation over time. This makes gastrointestinal physiology a multidimensional pharmacodynamic domain rather than a simple receptor-output relationship. Interpretation can be situated alongside obesity, weight management, clinical trials, pharmacodynamics, and clinical pharmacology.
| GI mechanism | Relevant signaling | Interpretive dimension |
|---|---|---|
| Gastric motor regulation | GLP-1-linked neural and smooth-muscle pathways | Temporal relationship to nutrient delivery |
| Gut-brain signaling | Peripheral and vagal signaling | Integration with appetite physiology |
| Postprandial regulation | Incretin and nutrient feedback | Interaction with endocrine and metabolic pathways |
Appetite-linked interpretation involves communication between peripheral nutrient sensing, vagal afferents, hypothalamic circuits, brainstem nuclei, and mesolimbic signaling. GLP-1 receptor activation is relevant to this distributed gut-brain network, making semaglutide mechanistically distinct from incretin agents whose receptor engagement differs. The framework connects appetite regulation, GLP-1 biology, mechanism, pharmacodynamics, and clinical pharmacology.
GIP receptor signaling may also intersect with central and peripheral metabolic networks, but its appetite-related interpretation should not be reduced to the GLP-1 pathway. Dual agonists introduce simultaneous GLP-1 and GIP receptor engagement, creating a mechanistic context in which central signaling, peripheral metabolism, endocrine feedback, and nutrient sensing may interact. Relevant frameworks include metabolic outcomes, obesity, weight management, mechanism, and pharmacodynamics.
Appetite responses are influenced by biological state, prior nutrient exposure, energy balance, receptor distribution, neural adaptation, and circulating drug exposure. Consequently, pharmacokinetic variation can modify the temporal profile of receptor stimulation without implying a fixed individual response. Mechanistic evidence can be integrated with pharmacokinetics, glycemic variability, insulin resistance, clinical trials, and effectiveness overview when evaluating appetite-related endpoints.
| Appetite pathway | Mechanistic components | Comparison relevance |
|---|---|---|
| Peripheral sensing | Gut, vagal and nutrient signals | Integration with receptor activation |
| Central regulation | Hypothalamic and brainstem circuits | GLP-1 and GIP pathway context |
| Systems integration | Endocrine, metabolic and neural feedback | Exposure-dependent pharmacodynamics |
Incretin receptor signaling intersects with metabolic physiology through pancreatic hormone regulation, hepatic glucose flux, adipose tissue signaling, skeletal muscle glucose handling, and nutrient partitioning. Semaglutide provides a GLP-1-centered mechanistic reference, while GIP-containing or dual-agonist approaches introduce additional receptor biology. Interpretation can be connected with insulin resistance, glycemic control, metabolic outcomes, GLP-1 biology, and mechanism.
Metabolic effects are not generated by a single tissue in isolation. Changes in insulin and glucagon can alter hepatic glucose production, while altered nutrient delivery can modify postprandial substrate availability. Changes in energy intake and gastrointestinal signaling can further interact with endocrine and metabolic feedback. These relationships can be considered through glycemic variability, appetite regulation, type 2 diabetes, prediabetes, and clinical pharmacology.
Comparative metabolic interpretation therefore requires attention to receptor pharmacology and physiological state simultaneously. Insulin sensitivity, baseline glucose regulation, endogenous incretin tone, nutritional status, hepatic metabolism, and tissue-specific receptor expression can all influence downstream signaling. The evidence framework can incorporate pharmacokinetics, pharmacodynamics, clinical trials, effectiveness overview, and metabolic outcomes without interpreting endpoints as treatment recommendations.
| Metabolic domain | Relevant pathway | Mechanistic variable |
|---|---|---|
| Hepatic glucose flux | Insulin, glucagon and nutrient signaling | Endocrine receptor activation |
| Peripheral glucose handling | Insulin-sensitive tissue pathways | Insulin sensitivity and metabolic state |
| Energy regulation | Appetite, nutrient and endocrine signals | Integrated incretin signaling |
Pharmacokinetics describes the concentration-time profile of an incretin-based agent, whereas pharmacodynamics describes the biological response generated by receptor engagement. For semaglutide and other incretin agents, these domains should be analyzed together because molecular stability, absorption, distribution, metabolism, elimination, receptor affinity, and signal transduction jointly shape pharmacological exposure. Core references include pharmacokinetics, pharmacodynamics, clinical pharmacology, mechanism, and GLP-1 biology.
Semaglutide's molecular characteristics support sustained GLP-1 receptor exposure, while other incretin agents can have different molecular structures and exposure profiles. A dual agonist additionally creates two receptor-specific pharmacodynamic dimensions that may have different relative activation characteristics. Comparative interpretation therefore considers concentration, receptor occupancy, intrinsic activity, receptor desensitization, downstream amplification, and temporal signaling. These concepts intersect with glycemic control, glycemic variability, appetite regulation, metabolic outcomes, and clinical trials.
PK/PD variability can arise from biological and analytical factors rather than from receptor biology alone. Differences in body composition, organ function, interacting physiology, assay characteristics, endogenous hormone concentrations, receptor expression, and baseline metabolic state may affect measured exposure or response relationships. Mechanistic interpretation therefore benefits from integrating pharmacokinetics, pharmacodynamics, insulin resistance, obesity, and clinical pharmacology rather than attributing every difference to receptor selectivity.
| PK/PD domain | Mechanistic question | Interpretive relevance |
|---|---|---|
| Exposure | What concentration-time profile reaches target tissues? | Temporal receptor engagement |
| Receptor pharmacology | How does ligand exposure translate into receptor signaling? | Affinity, intrinsic activity and occupancy |
| Systems response | How does signaling propagate across physiology? | Integrated endocrine, GI and metabolic effects |
Mechanistic response variability reflects differences in exposure, receptor biology, tissue distribution, endogenous physiology, and downstream signal processing. Semaglutide exposure may be interpreted through its GLP-1 receptor pharmacology, whereas GIP-containing and dual agonists add receptor-specific variables. Relevant analytical domains include pharmacokinetics, pharmacodynamics, GLP-1 biology, mechanism, and clinical pharmacology.
Biological heterogeneity can arise from differences in receptor expression, intracellular signaling competence, autonomic tone, insulin sensitivity, endogenous incretin physiology, gastric motor function, and central appetite circuitry. The same circulating concentration does not necessarily represent identical tissue-level signaling across physiological states. Comparative interpretation can therefore incorporate insulin resistance, glycemic variability, appetite regulation, metabolic outcomes, and type 2 diabetes as contextual variables.
Evidence variability also depends on study design, biomarker selection, receptor-specific assays, sampling time, endpoint definitions, and population characteristics. Mechanistic evidence can therefore produce different apparent relationships depending on whether studies measure receptor activation, hormone concentrations, glucose dynamics, gastrointestinal physiology, appetite signals, or integrated metabolic endpoints. These considerations connect clinical trials, effectiveness overview, pharmacokinetics, pharmacodynamics, and clinical pharmacology.
| Source of variability | Mechanistic effect | Interpretive layer |
|---|---|---|
| Exposure variability | Changes concentration-time profile | PK |
| Receptor variability | Changes signaling sensitivity or capacity | PD |
| Physiological variability | Changes integrated endocrine and metabolic response | Systems physiology |
Glycemic endpoints can serve as downstream readouts of incretin pharmacology, but they do not identify a single causal pathway by themselves. GLP-1 receptor activation, GIP receptor activation, insulin secretion, glucagon regulation, gastric emptying, nutrient delivery, and insulin sensitivity can all contribute to glucose dynamics. Mechanistic interpretation can therefore incorporate glycemic control, glycemic variability, GLP-1 biology, insulin resistance, and mechanism.
Comparing semaglutide with other incretin agents requires attention to whether an endpoint reflects direct receptor pharmacology or a secondary systems response. For example, a change in postprandial glucose can involve altered insulin secretion, glucagon physiology, gastric nutrient delivery, and hepatic glucose flux simultaneously. This framework connects pharmacodynamics, pharmacokinetics, clinical pharmacology, type 2 diabetes, and prediabetes.
Glycemic variability is similarly multidimensional because glucose excursions reflect meal composition, nutrient absorption, insulin secretion, glucagon signaling, tissue glucose uptake, and hepatic glucose production. Comparative incretin studies can therefore be interpreted through integrated pathway models rather than isolated endpoint values. Relevant evidence contexts include glycemic variability, glycemic control, clinical trials, metabolic outcomes, and effectiveness overview.
| Glycemic endpoint | Potential mechanistic contributors | Interpretive role |
|---|---|---|
| Fasting glucose | Hepatic glucose production and endocrine signaling | Integrated metabolic readout |
| Postprandial glucose | Insulin, glucagon, gastric emptying and nutrient flux | Meal-related systems response |
| Glycemic variability | Multiple temporal glucose-regulating pathways | Dynamic PD-related endpoint |
A systems-level comparison integrates receptor pharmacology with endocrine, gastrointestinal, neural, and metabolic physiology. Semaglutide can be viewed as a GLP-1 receptor-centered intervention within this network, while GIP agonists and dual agonists introduce additional receptor signaling. The integrated framework draws on GLP-1 biology, mechanism, clinical pharmacology, pharmacokinetics, and pharmacodynamics.
At the endocrine level, receptor activation influences pancreatic hormone signaling; at the gastrointestinal level, incretin pathways interact with gastric and intestinal physiology; at the appetite level, peripheral signals communicate with central neural circuits; and at the metabolic level, endocrine and nutrient signals influence glucose and energy regulation. These domains connect with glycemic control, appetite regulation, insulin resistance, metabolic outcomes, and glycemic variability.
The final interpretive layer is evidence integration. Molecular pharmacology establishes receptor mechanisms, translational physiology links signaling to organ systems, PK/PD analysis connects exposure with biological activity, and clinical research provides observations in defined populations. These evidence types answer different questions and should not be treated as interchangeable. Comparative interpretation can therefore integrate clinical trials, effectiveness overview, type 2 diabetes, obesity, and weight management while retaining a mechanistic focus.
| System level | Primary pathway | Integration point |
|---|---|---|
| Molecular | GLP-1 and GIP receptor signaling | Ligand-receptor pharmacology |
| Organ-system | Pancreatic, gastrointestinal and neural signaling | Endocrine and physiological integration |
| Whole-body | Glucose, appetite and metabolic regulation | PK/PD-linked systems response |
The mechanistic concept compares semaglutide, a GLP-1 receptor agonist, with the broader class of incretin-based pharmacology. Incretin biology includes GLP-1 receptor signaling, GIP receptor signaling, and pharmacological combinations that engage both receptors. The comparison therefore concerns receptor identity, intracellular signaling, tissue distribution, exposure-response relationships, and downstream endocrine, gastrointestinal, appetite, and metabolic pathways rather than a simple comparison of therapeutic effects.
GLP-1 and GIP receptors are both class B1 G protein-coupled receptors and can activate cyclic AMP-associated intracellular signaling, but their tissue distribution and physiological roles are not identical. GLP-1 receptor biology is closely associated with pancreatic, gastrointestinal, neural, and metabolic signaling, whereas GIP receptor biology has distinct endocrine and metabolic characteristics. Mechanistic comparison therefore requires consideration of receptor expression, cellular context, ligand exposure, downstream signaling, and physiological state.
GLP-1 agonism primarily engages the GLP-1 receptor, whereas a dual agonist pharmacologically engages both GLP-1 and GIP receptors. Dual-receptor activation introduces an additional signaling dimension because receptor occupancy, tissue distribution, intracellular coupling, signal amplification, and temporal exposure can differ between the two pathways. The resulting biology should not be assumed to equal a simple additive combination of isolated GLP-1 and GIP effects, because receptor pathways can interact within shared physiological systems.
Pharmacokinetics describes drug exposure over time, while pharmacodynamics describes the biological response associated with that exposure. In incretin pharmacology, molecular stability, distribution, elimination, receptor affinity, receptor occupancy, and intracellular signaling jointly determine the relationship between circulating concentration and physiological activity. Comparing PK and PD can therefore help distinguish differences caused by exposure profiles from differences related to receptor selectivity, dual-receptor engagement, intrinsic activity, or downstream biological signaling.
Endocrine-linked comparison focuses particularly on pancreatic islet signaling and glucose-dependent hormone regulation. GLP-1 and GIP receptor activation can influence cyclic AMP signaling in endocrine cells, affecting insulin and glucagon physiology in context-dependent ways. Differences in receptor distribution, ligand exposure, ambient glucose, endogenous hormone concentrations, and cellular signaling capacity can modify the observed response. These mechanisms are interpreted as interconnected endocrine processes rather than as isolated receptor effects.
Gastrointestinal interpretation includes receptor-associated regulation of gastric motor function, nutrient delivery, gut-brain communication, and postprandial endocrine signaling. GLP-1 pathways have established physiological relationships with gastrointestinal function, while GIP and dual-receptor pathways introduce different receptor and tissue contexts. Mechanistic interpretation must distinguish direct receptor-associated signaling from secondary effects produced by altered nutrient transit, gastric distension, vagal signaling, and downstream endocrine feedback.
Appetite-related incretin biology involves communication among gastrointestinal nutrient sensing, vagal afferents, brainstem nuclei, hypothalamic circuits, and other central neural systems. GLP-1 receptor activation is relevant to this gut-brain network, while GIP receptor and dual-agonist biology introduces additional receptor-specific signaling. Interpretation depends on receptor distribution, exposure, neural integration, metabolic state, and endogenous nutrient signals. Appetite-related observations therefore represent an integrated physiological response rather than a single isolated receptor event.
Relevant metabolic pathways include pancreatic insulin and glucagon signaling, hepatic glucose production, peripheral glucose utilization, nutrient partitioning, energy intake, and interactions with insulin sensitivity. GLP-1 receptor activation provides one mechanistic entry point, while GIP receptor activation and dual agonism introduce additional signaling. The resulting physiology reflects coordinated communication among endocrine organs and metabolic tissues, with receptor expression, exposure, nutrient status, and baseline metabolic state influencing downstream signaling.
Mechanistic response variability can arise from pharmacokinetic exposure, receptor expression, tissue distribution, intracellular signaling capacity, endogenous incretin physiology, metabolic state, gastrointestinal function, and neural signaling. Differences in molecular structure can also alter stability, distribution, receptor interaction, and duration of pharmacological activity. Consequently, observed biological responses may reflect several interacting variables rather than a single property of the drug or receptor. Experimental design and endpoint selection can further influence apparent mechanistic relationships.
Glycemic endpoints are downstream measures that can reflect multiple incretin-linked mechanisms simultaneously. Changes in glucose dynamics may involve insulin secretion, glucagon regulation, gastric nutrient delivery, hepatic glucose production, peripheral glucose uptake, and insulin sensitivity. A glycemic measurement therefore does not identify one receptor pathway by itself. Mechanistic interpretation is strengthened when glucose endpoints are considered alongside receptor pharmacology, hormone measurements, exposure data, gastrointestinal physiology, and other relevant pharmacodynamic signals.
Metabolic endpoints represent integrated physiological responses involving endocrine signaling, nutrient intake, hepatic metabolism, adipose tissue, skeletal muscle, and energy regulation. A difference between agents cannot automatically be attributed to receptor selectivity because exposure, baseline metabolic state, insulin sensitivity, nutrient flux, and downstream pathway interactions may also contribute. Mechanistic interpretation therefore separates direct receptor-mediated events from secondary systemic responses and considers the temporal relationship between pharmacological exposure and metabolic physiology.
Appetite endpoints reflect a complex interaction among peripheral nutrient sensing, gastrointestinal signaling, vagal pathways, brainstem circuits, hypothalamic regulation, reward-related neural networks, and metabolic feedback. GLP-1 receptor signaling is one component of this network, while GIP receptor and dual-agonist biology add other receptor-specific mechanisms. Interpretation should therefore consider exposure, receptor distribution, physiological state, neural integration, and measurement methodology rather than treating an appetite endpoint as a direct and isolated measure of receptor activation.
Mechanistic evidence establishes how receptor engagement can translate into cellular signaling, organ-level physiology, and integrated endocrine or metabolic responses. Molecular studies clarify receptor pharmacology, translational studies connect pathways with physiological systems, PK/PD studies relate exposure to biological activity, and clinical research evaluates these mechanisms in defined populations. Each evidence type answers a different question. A mechanistic comparison is therefore most informative when receptor biology, exposure-response relationships, physiological context, and observed endpoints are interpreted together.